Study of ATR 1072 for PRKAG2 syndrome
Part of Genetic & congenital, Heart & circulation, Hormones & metabolism clinical trials.
This trial tests a new medicine called ATR 1072 for people with PRKAG2 syndrome, a genetic heart condition. It aims to see if the drug is safe and can help manage symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have a confirmed genetic change in the PRKAG2 gene (even if it's unclear if it causes the condition).
- You have signs or symptoms of PRKAG2 syndrome, like heart problems.
- You are willing to follow study rules and have heart muscle biopsies if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at genetic factors in people with atrial fibrillation (an irregular heartbeat) and weak heart function to understand why some people's hearts recover after treatment and others don't. Researchers will collect blood samples and medical information to identify genetic patterns.
This Phase 1 trial tests RP-A601 (a gene-delivery type treatment) to see if it can reduce dangerous heart rhythm problems in people with PKP2-related arrhythmogenic cardiomyopathy (ACM). Because it’s an early safety/dose study, the main goal is to check safety and how the body responds.
This study looks at how plakophilin 2 (PKP2)-related arrhythmogenic right ventricular cardiomyopathy (ARVC) progresses over time. You'll give blood samples to check for antibodies to a virus used in gene therapy, and help doctors understand the disease better.
This trial tests a new gene therapy called TN-401 for people with ARVC caused by a specific PKP2 gene mutation. The goal is to see if the treatment is safe and can help reduce dangerous heart rhythms.
This study is for people with a specific genetic heart condition (PKP2-related arrhythmogenic cardiomyopathy) who already have an ICD. It does not test a new treatment but instead follows participants over time to learn more about the condition.
This study follows people with a confirmed PKP2 genetic mutation and arrhythmogenic cardiomyopathy (ACM) to understand how their condition changes over time. It may help doctors learn more about the disease and plan future treatments.
Hear when a new Cardiac Glycogenosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.